Stock Events

Stock Events

Nurix Therapeutics 

$26.21
34
-$0.66-2.47% Friday 20:00
+$0.33+1.26%Friday 23:53After hours

Statistics

Day High
26.22
Day Low
26.15
52W High
28.23
52W Low
8.2
Volume
19,220
Avg. Volume
-
Mkt Cap
2.72B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.03
-0.86
-0.69
-0.52
Expected EPS
-0.611033
Actual EPS
N/A

Financials

-314.9%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
83.98MRevenue
-264.46MNet Income

Analyst Ratings

34.67Average Price Target
The highest estimate is 45.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NRIX. It's not an investment recommendation.
Broadcom
9
AVGO
ExxonMobil
9
XOM
SoFi Technologies
9
SOFI
Eos Energy Enterprises
9
EOSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is involved in gene editing, a technology that could potentially compete with Nurix's targeted protein modulation.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, directly competing in the innovative therapeutic area that Nurix operates in.
Editas Medicine
EDIT
Mkt Cap477.63M
Editas Medicine operates in the genome editing field, specifically CRISPR technology, which is a direct competitor to Nurix's approach in drug development.
Beam Therapeutics
BEAM
Mkt Cap3.07B
Beam Therapeutics focuses on precision genetic medicines using base editing, a novel form of genome editing that could rival Nurix's protein degradation and modulation technologies.
Allogene Therapeutics
ALLO
Mkt Cap722.08M
Allogene Therapeutics is focused on allogeneic CAR T cell therapies, which could compete with Nurix's efforts in cancer and immune disorder treatments.
Fate Therapeutics
FATE
Mkt Cap279.18M
Fate Therapeutics is working on programmed cellular immunotherapies, which could be seen as a competitor to Nurix's approach in manipulating protein levels for cancer therapy.
Adaptive Biotechnologies
ADPT
Mkt Cap4.15B
Adaptive Biotechnologies is advancing the field of immune-driven medicine, which could compete with Nurix's work on targeting the protein degradation pathway for cancer treatment.
Novartis
NVS
Mkt Cap301.95B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Nurix is active, making it a competitor due to its scale and breadth of research.

About

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Show more...
CEO
Arthur T. Sands
Employees
357
Country
United States
ISIN
US67080M1036

Listings

XNAS
US
NRIX
BOATS
BOATS
NRIX.BOATS

0 Comments

Share your thoughts

FAQ

What is Nurix Therapeutics stock price today?▼
The current price of NRIX is $26.21 USD — it has decreased by -2.47% in the past 24 hours. Watch Nurix Therapeutics stock price performance more closely on the chart.
What is Nurix Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Nurix Therapeutics stocks are traded under the ticker NRIX.
Is Nurix Therapeutics stock price growing?▼
NRIX stock has fallen by -1.91% compared to the previous week, the month change is a +11.15% rise, over the last year Nurix Therapeutics has showed a +180.62% increase.
What is Nurix Therapeutics market cap?▼
Today Nurix Therapeutics has the market capitalization of 2.72B
When is the next Nurix Therapeutics earnings date?▼
Nurix Therapeutics is going to release the next earnings report on October 09, 2026.
What were Nurix Therapeutics earnings last quarter?▼
NRIX earnings for the last quarter are -0.81 USD per share, whereas the estimation was -0.72 USD resulting in a -12.05% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nurix Therapeutics revenue for the last year?▼
Nurix Therapeutics revenue for the last year amounts to 83.98M USD.
What is Nurix Therapeutics net income for the last year?▼
NRIX net income for the last year is -264.46M USD.
How many employees does Nurix Therapeutics have?▼
As of August 30, 2026, the company has 357 employees.
In which sector is Nurix Therapeutics located?▼
Nurix Therapeutics operates in the Health & Wellness sector.
When did Nurix Therapeutics complete a stock split?▼
Nurix Therapeutics has not had any recent stock splits.
Where is Nurix Therapeutics headquartered?▼
Nurix Therapeutics is headquartered in BRISBANE, United States.